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Abstract
Background: A database analysis was conducted to assess 
the effectiveness of sucroferric oxyhydroxide (SO) on lower-
ing serum phosphorus and phosphate binder (PB) pill bur-
den among adult peritoneal dialysis (PD) patients prescribed 
SO as part of routine care. Methods: Adult PD patients (n = 
258) prescribed SO through a renal pharmacy service were 
analyzed. Baseline was 3 months before SO prescription. SO-
treated follow-up was for 6 months or until either a new PB 
was prescribed, SO was not refilled, PD modality changed, or 
patient was discharged. In-range serum phosphorus was de-
fined as ≤5.5 mg/dL. Results: At baseline, mean serum phos-
phorus was 6.59 mg/dL with 10 prescribed PB pills/day. The 
proportion of patients achieving in-range serum phospho-
rus increased by 72% from baseline to month 6. Prescribed 
PB pills/day decreased by 57% (10 at baseline to 4.3 at SO 
follow-up, p < 0.0001). The mean length of SO follow-up was 
5.1 months; SO follow-up ended for 38, 27, and 50 patients 
at months 4, 5, and 6, respectively, due to no further PB fills, 
and for 10, 11, and 4 patients at months 4, 5, and 6, respec-
tively, due to another PB prescribed. In patients with base-
line serum phosphorus >5.5 mg/dL who achieved in-range 
serum phosphorus during SO follow-up for ≥1 quarter, a no-
table improvement in serum phosphorus (6.54 to 5.10 mg/
dL, p < 0.0001) was observed, and there was a 53% reduction 
in PB pill burden (9.9 to 4.7, p < 0.0001). Conclusion: Among 
PD patients prescribed SO as part of routine care, improve-
ments in serum phosphorus control and >50% reduction in 
PB pills/day were observed. © 2018 The Author(s) 
Published by S. Karger AG, Basel
Background
Peritoneal dialysis (PD) represents a safe and cost-ef-
fective treatment modality for patients with end-stage re-
nal disease (ESRD) [1–4]. In the United States, by the end 
of 2014, 6.9% of prevalent ESRD cases were treated with 
PD [5]. Disorders of phosphorus metabolism among 
ESRD patients are common, with serum phosphorus lev-
els in PD patients generally lower than in hemodialysis 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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(HD) patients [6–8], though treatment with oral phos-
phate binders (PBs) are usually indicated [9]. Favorable 
properties of PBs would include low pill burden, low cost, 
minimal systemic absorption, and minimal side effects [6, 
10]. Potential risks include toxicity, gastrointestinal side 
effects, and contribution to hypercalcemia [11–13]. Ad-
herence to PB therapy is essential for phosphorus control, 
and low pill burden may be a key factor in adherence [14–
16]. PD patients are prescribed, on average, 16–19 pills/
day [17, 18] and half are PBs [18]. 
Sucroferric oxyhydroxide (SO) is an iron-based, chew-
able PB with a low pill burden indicated for treatment of 
hyperphosphatemia in patients with chronic kidney dis-
ease on dialysis. Coyne et al. [19] reported significantly 
decreased pill burden and improved serum phosphorus 
levels among HD patients prescribed SO as part of rou-
tine clinical care. Floege et al. [20] reported results from 
a phase 3 randomized controlled trial and found SO to be 
non-inferior to sevelamer carbonate for the control of se-
rum phosphorus in PD patients, with a lower pill burden. 
The objective of this retrospective database analysis was 
to assess the effectiveness of SO on lowering serum phos-
phorus levels and PB pill burden among adult PD patients 
prescribed SO as part of routine clinical care. 
Methods
SO (Velphoro®, Fresenius Medical Care Renal Therapies 
Group, Waltham, MA, USA) is usually prescribed with a starting 
dose of 3 pills/day, administered as 1 tablet with each meal and ti-
trated in increments or decrements of 1 tablet per day.
Adult (age >18 years) PD patients who were prescribed SO as 
part of routine clinical care at Fresenius Kidney Care (FKC) facili-
ties and who received their first SO prescription through Frese-
niusRx (a specialty renal pharmacy service) between April 1, 2014 
and October 30, 2015, were included in this retrospective analysis. 
Patients were required to have ≥3 months of SO prescription fills 
recorded, uninterrupted by another PB. De-identified demo-
graphic and clinical data were retrieved from the FKC data ware-
house; PB prescription information originated from the Fresenius-
Rx database. To supplement baseline PB information, we used PB 
orders from the FKC Electronic Health Record (EHR). However, 
we cannot assume that the orders recorded in this database are as 
precise or accurate as documented prescription fills; thus, only 
documented prescriptions were used for calculations of PB pills 
per day. Treatment periods for assessment and comparison were 
defined as baseline (BL; 3 months before SO prescription), and SO-
treated follow-up (SO; up to 6 months of SO prescription). SO-
treated follow-up was 6 months or until either a new PB was pre-
scribed, SO was not refilled, PD modality changed, or patient was 
discharged from FKC. 
Basic demographic and treatment characteristics were evalu-
ated at baseline. Clinical parameters included PB pills/day, min-
eral and bone disease markers (serum phosphorus, serum calcium, 
intact parathyroid hormone [iPTH]), nutritional and clearance 
parameters (weight, serum albumin, normalized protein catabolic 
rate [nPCR], serum creatinine, total Kt/V [PD + residual renal 
function], PD Kt/V, and residual urea clearance [Kru]); and anemia 
and iron indices (ferritin, transferrin saturation [TSAT], hemoglo-
bin, and iron). Laboratory tests were measured monthly, except for 
ferritin and iPTH, which were measured quarterly. Calcium was 
albumin-corrected using the Payne’s formula [21]. Serum albumin 
and nPCR were each divided by serum phosphorus to calculate 
phosphorus-attuned albumin and nPCR. Baseline Kru was catego-
rized into 3 groups: unavailable; ≤3 mL/min/1.73 m2; and >3.0 mL/
min/1.73 m2. Spectra Laboratories (Rockleigh, NJ, USA) per-
formed all laboratory tests.
Repeated-measures data were analyzed using linear mixed-ef-
fects regression. Mean clinical measures were summarized using 
least-squared means and compared between baseline and SO fol-
low-up. In-range serum phosphorus was defined as mean serum 
phosphorus ≤5.5 mg/dL. To determine the impact of intermittent 
HD on changes in serum phosphorus, an analysis was conducted 
where all serum phosphorus levels were deleted for months when 
patients had intermittent HD (n = 23). A sub-group analysis was 
conducted for all patients achieving serum phosphorus ≤5.5 mg/
dL during at least 1 quarter of SO follow-up and a subset of these 
patients with baseline serum phosphorus >5.5 mg/dL. Sub-analy-
sis by Kru group was conducted to assess effect measure modifica-
tion by residual renal function. For this sub-analysis, missing base-
line Kru were imputed for 33 patients with follow-up Kru measured. 
Serum phosphorus levels were compared for subgroups that did 
and did not complete 6 months of SO treatment. P values <0.05 
were considered statistically significant. All analyses were con-
ducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
This database analysis was approved by the New England Institu-
tional Review Board.
Results
Analysis of Study Cohort (n = 258)
In total, 258 patients met the requirements for analy-
sis. Patients were, on average, 50.6 ± 13.9 years old, with 
a mean dialysis vintage of 29.3 ± 27.6 months (Table 1). 
The majority of patients (76%) received continuous cy-
cling PD (CCPD), 13.2% received continuous ambula-
tory PD (CAPD), and the remaining patients (10.8%) 
switched from CAPD to CCPD during baseline. On aver-
age, patients were prescribed 4.9 ± 1 exchanges per day 
and 6.8 ± 0.6 days per week. The mean length of SO fol-
low-up was 5.1 months; 151 patients did not complete all 
6 months of SO monotherapy. SO follow-up ended for 38, 
27, and 50 patients at months 4, 5, and 6, respectively, due 
to no further PB fills, and for 10, 11, and 4 patients at 
months 4, 5, and 6, respectively, due to another PB pre-
scribed. The other 11 patients who did not complete the 
6 months were discharged from the clinic or switched to 
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HD. (See monthly patient disposition in online suppl. Ta-
ble S1; for all online suppl. material, see www.karger.com/
doi/10.1159/000487856). The majority of patients with 
PB fills from FreseniusRx at baseline (n = 92) were pre-
scribed sevelamer (63.0%), followed by calcium acetate 
(20.7%), more than 1 PB (10.9%) and lanthanum carbon-
ate (5.4%). The remainder of patients (n = 166) had no 
recorded baseline PB fills in the FreseniusRx database. 
Among the 166 patients who did not receive a Fresenius-
Rx PB fill during baseline, 110 patients had PB prescrip-
tions available through the FKC EHR database. Figure 1 
shows that the distribution of PB type was similar at base-
line for patients with and without PB prescriptions 
through FreseniusRx. 
Mean changes between baseline and SO follow-up are 
compared in Table 2. A significant improvement was ob-
served in mean serum phosphorus (6.59 mg/dL at BL to 
6.26 mg/dL at SO, p < 0.0001). Prescribed PB pills/day 
decreased by 57% from 10 pills/day at baseline to 4.3 pills/
day at SO follow-up (p < 0.0001). There was a slight de-
crease in corrected calcium (9.36 to 9.31 mg/dL, p = 0.018) 
and a slight increase in intact PTH from 468 to 497 pg/
mL (p = 0.03). There were no changes observed in unad-
justed nPCR (1.0 g/kg/day at BL and SO, p  = 0.9) and 
weight (86.8 to 86.9 kg, p = 0.8), but a slight decrease was 
observed in unadjusted serum albumin from 3.70 to 3.62 
g/dL (p < 0.0001). When adjusted for serum phosphorus, 
increases were observed in phosphorus-attuned albumin 
from 0.6 × 103 at BL to 0.63 × 103 at SO follow-up (p < 
0.0001), and phosphorus-attuned nPCR (0.17 × 103 to 
0.18 ×103 dL/kg/day, p  = 0.04). Although there was a 
slight decrease in Kru (2.85 to 2.47 mL/min/1.73 m2, p = 
0.008) and increase in serum creatinine (12.0 to 12.2 mg/
dL, p = 0.001), there were no changes in total Kt/V (2.1 at 
BL and SO, p = 0.7) and a numeric increase in PD Kt/V 
(1.65 to 1.70, p = 0.5). 
As a sensitivity analysis, several subgroup analyses on 
serum phosphorus changes were conducted. There were 
21 patients who received intermittent HD during the 
study periods. Changes in serum phosphorus levels after 
removing these measurements showed a similar im-
provement in serum phosphorus (6.60 to 6.25 mg/dL, p < 
0.0001). Patients who completed the full 6 months of SO 
follow-up (n = 107) had serum phosphorus reduced from 
6.56 mg/dL at BL to 6.16 mg/dL at SO follow-up (p  < 
0.0001). PB pill burden reduced from 9.9 to 4.3 pills/day 
(p < 0.0001) for the patients prescribed PB at baseline (92 
patients out of the 107). Patients with PB prescriptions 
recorded through FreseniusRx at baseline and who com-
pleted the 6-month follow-up (n = 30) had a mean serum 
phosphorus decrease from 6.33 mg/dL at baseline month 
–1 (month before switch to SO) to 5.37 mg/dL at month 
6 of SO follow-up (p < 0.001) and percentage of patients 
achieving in-range serum phosphorus levels increased 
from 11 (29.7%) patients at baseline month –1 to 18 
(48.6%) patients at SO follow-up month 6. Patients with 
PB prescriptions recorded through FreseniusRx or FKC 
Table 1. Baseline characteristics at SO therapy initiation
Baseline characteristic Study cohort
(n = 258)
Age, years 50.6±13.9
Dialysis vintage, months 29.3±27.5
BMI, kg/m2 30.4±8
Gender, male, n (%) 143 (55.4)
Race, n (%)
White 160 (62.0)
African American 64 (24.8) 
Other 34 (13.2)
Diabetes, n (%) 121 (46.9)
Primary cause of ESRD, n (%)
Diabetes mellitus 90 (34.9)
Hypertension 69 (26.7)
Glomerulonephritis 47 (18.2)
Polycystic kidney disease 10 (3.9)
Other 34 (13.2)
Unknown 8 (3.1)
Baseline PB dispensed through FreseniusRx
No PB recorded, n (%) 166 (64.3)
PB recorded in the FKC EHR database, n (%) 110 (66.3)
PB recorded, n (%) 92 (35.7)
Calcium acetate, n (%) 19 (20.7)
Lanthanum carbonate, n (%) 5 (5.4)
Sevelamer, n (%) 58 (63.0)
>1 PB recorded, n (%) 10 (10.8)
PD modality, n (%)
Manual (CAPD) 34 (13.2)
Automated (CCPD) 196 (76)
Switched (CAPD to CCPD) 28 (10.8)
Clinical parameters
Serum phosphorus, mg/dL 6.5±1.4
Albumin-corrected calcium, mg/dL 9.4±0.7
Intact PTH, pg/mL 459±317
Serum albumin, g/dL 3.7±0.4
Kru, mL/min/1.73 m2 2.72±2.45
PD Kt/V 1.7±0.4
Total Kt/V 2.2±0.5
Values are expressed as mean ± SD, or n (%).
BMI, body mass index (kg/m2); CAPD, continuous ambulatory 
PD; CCPD, continuous cycling PD; Kru, residual urea clearance; 
FKC EHR, Fresenius Kidney Care Electronic Health Records; PB, 
phosphate binder; PD, peritoneal dialysis; PTH, parathyroid hor-
mone; ESRD, end-stage renal disease.
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EHR database at baseline and who completed the 6-month 
follow-up (n  = 84) had a mean serum phosphorus de-
crease from 6.90 mg/dL at baseline month –1 to 5.94 mg/
dL at SO follow-up month 6 (p < 0.0001) and the percent-
age of patients achieving in-range serum phosphorus lev-
els increased from 21 (25%) patients at baseline month –1 
to 34 (40.5%) at SO follow-up month 6. An additional 
analysis of patients who did not complete the full 6 months 
of SO follow-up was conducted using all serum phospho-
rus measurements available, regardless of the end of SO 
monotherapy prescription, and they had a mean serum 
phosphorus of 6.62 at BL and 6.34 mg/dL at follow-up 
(p < 0.001).
At baseline, 127 (49.2%) patients received IV iron ther-
apy and 195 (75.6%) patients received erythropoietin-
stimulating agent therapy. At SO follow-up, 132 (51.1%) 
patients received IV iron therapy (iron sucrose) and 200 
(77.5%) patients received erythropoietin-stimulating 
agent therapy. Mean iron sucrose dose was minimally 
changed from 202 mg/month at BL to 204 mg/month at 
SO follow-up (p = 0.6). Similarly, mean epoetin alfa dose 
was minimally changed from 11,805 to 11,667 units/
month (p = 0.5) among patients treated exclusively with 
epoetin alfa (83%). Among patients who received IV iron 
therapy (n = 165), significant increases in ferritin (748 to 
940 ng/mL, p < 0.0001), TSAT (34.0 to 38.4%, p < 0.0001) 
and hemoglobin (10.6 to 10.7 g/dL, p = 0.08) were ob-
served from baseline to SO follow-up. Among patients 
who did not receive any IV iron therapy (n = 93), serum 
ferritin increased from 801 to 876 ng/mL (p = 0.02), he-
moglobin increased from 11.2 to 11.3 g/dL (p = 0.03) and 
TSAT was unchanged (38.5%, p = 0.9).
The percentage of patients achieving in-range serum 
phosphorus (≤5.5 mg/dL) increased from baseline to SO 
follow-up (Fig. 2). At baseline 30.1, 25.4, and 25.8% of 
patients were in-range for serum phosphorus at months 
–3, –2, and –1 respectively. During SO follow-up, the per-
cent of patients who were in-range for serum phosphorus 
increased to 35.3, 37.5, 41.8, 36.8, 38.9, and 44.4% at 
months 1–6, respectively. Comparing BL month –1 to SO 
follow-up month 6, there was a 72% increase in patients 
achieving in-range serum phosphorus along with >50% 
reduction in PB pills/day.
Analysis of Patients with In-Range Serum Phosphorus 
Recorded During SO Follow-Up
Patients (n = 110) who achieved in-range serum phos-
phorus during ≥1 quarter of SO follow-up were analyzed 
to determine the associated effects of being in-range on 
other mineral bone disease and nutrition markers (Table 
3). Among these patients, 75 patients (68%) had a record-
ed PB at baseline (67% sevelamer, 27% calcium acetate, 







through FKC EHR database
(n = 110)
Sevelamer
n = 58 (63%)
Sevelamer
n = 65 (59%)
Calcium acetate
n = 19 (21%)
Calcium acetate
n = 22 (20%)
Lanthanum carbonate
n = 5 (5%)
Lanthanum carbonate
n = 8 (7%)
>1 PB*
n = 10 (11%)
>1 PB*







through FKC EHR database
(n = 56)
Fig. 1. Baseline PB prescriptions prior to 
SO initiation. * Combination of sevelamer, 
calcium acetate, and/or lanthanum car-
bonate.  FKC EHR, Fresenius Kidney Care 
Electronic Heath Record database; PB, 
phosphate binder.
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4% lanthanum carbonate, and 3% PB combination thera-
py), and 35 patients (32%) did not have a recorded PB at 
baseline (for prescriptions by month, see online suppl. 
Table S2). Comparing baseline and SO follow-up, a >50% 
reduction in PB pill burden (9.3 to 4.4 pills/day, p < 0.0001) 
and an improvement in serum phosphorus (5.81 to 4.97 
mg/dL, p < 0.0001) were observed. Intact PTH was un-
changed (406 to 425 pg/mL, p = 0.4). There was a slight 
decrease in corrected calcium (9.43 to 9.36 mg/dL, p  = 
0.08) and serum albumin (3.70 to 3.64 g/dL, p < 0.001), 
and no changes observed in nPCR (1.0 g/kg/day, p = 0.2). 
Comparing baseline and SO follow-up, there were signif-
icant improvements in phosphorus-attuned albumin 
(0.68 × 103 to 0.77 × 103, p < 0.0001) and phosphorus-at-
tuned nPCR (0.18 × 103 to 0.21 × 103 dL/kg/day, p < 0.001). 
Among patients who achieved in-range serum phos-
phorus during SO follow-up, 97 patients did not change 
PD prescription modality (86% CCPD, 14% CAPD, 
mean serum phosphorus 5.69 mg/dL at baseline and 4.94 
mg/dL at SO follow-up, p < 0.0001), and 13 patients were 
prescribed a switch between both PD modalities (mean 
serum phosphorus was 6.42 mg/dL at baseline and 4.92 
mg/dL at SO follow-up, p < 0.001). Fifty-nine patients 
did not change the prescribed number of PD exchanges/
day (mean number of PD exchanges = 4.7/day, mean se-
rum phosphorus 5.57 mg/dL at baseline and 5.02 mg/dL 
at SO follow-up, p < 0.0001). Fifty-one patients had an 
increase in prescribed number of PD exchanges/day 
(mean  = 4.8/day at baseline and 5.2/day at follow-up) 
and had a mean serum phosphorus of 6.03 mg/dL at 
Table 2. Comparison of clinical parameters between baseline and SO therapy (258 PD patients)
Parameter Baseline SO follow-up p value
PB pills/day* 10.0 (0.2) 4.3 (0.2) <0.0001
Mineral and bone disease markers
Serum phosphorus, mg/dL 6.59 (0.09) 6.26 (0.09) <0.0001
Albumin-corrected calcium, mg/dL 9.36 (0.04) 9.31 (0.04) 0.018
Intact PTH, pg/mL 468 (23) 497 (22) 0.032
Nutritional and clearance parameters
Weight, kg 86.8 (1.5) 86.9 (1.5) 0.8
Serum albumin, g/dL 3.70 (0.02) 3.62 (0.02) <0.0001
Phosphorus-attuned albumin, ×103 0.6 (0.01) 0.63 (0.01) <0.0001
nPCR, g/kg/day 1.0 (0.03) 1.0 (0.02) 0.9
Phosphorus-attuned nPCR, ×103 dL/kg/day 0.17 (0.005) 0.18 (0.004) 0.044
Serum creatinine, mg/dL 12.0 (0.3) 12.2 (0.3) 0.001
Kru, mL/min/1.73 m2 2.85 (0.20) 2.47 (0.19) 0.008
PD Kt/V 1.65 (0.05) 1.70 (0.04) 0.5
Total Kt/V 2.1 (0.06) 2.1 (0.05) 0.7
Anemia and iron indices
Patients not receiving IV iron therapy (n = 93)
Ferritin, ng/mL 801 (66) 876 (65) 0.018
Transferrin saturation, n (%) 38.5 (1.4) 38.5 (1.3) 0.9
Hemoglobin, g/dL 11.2 (0.2) 11.3 (0.2) 0.039
Iron, mcg/dL 98.1 (3.5) 93.2 (3.2) 0.077
Patients receiving IV iron therapy (n = 165)
Ferritin, ng/mL 748 (36) 940 (34) <0.0001
Transferrin saturation, n (%) 34.0 (0.9) 38.4 (0.8) <0.0001
Hemoglobin, g/dL 10.6 (0.1) 10.7 (0.1) 0.078
Iron, mcg/dL 85.8 (2.4) 92.3 (2.1) 0.005
Values are expressed as least-squared means (SE), p values compare least-squared means between treatment 
periods. 
* Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx 
(n = 92). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n = 166) 
was found to be 4.3 SO pills/day.
Kru, residual urea clearance; nPCR, normalized protein catabolic rate; PD, peritoneal dialysis; PTH, parathy-
roid hormone; SO, sucroferric oxyhydroxide; PB, phosphate binder.
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baseline and 4.83 mg/dL at SO follow-up (p < 0.0001). 
Eighty-three patients received 7 days/week of PD treat-
ment throughout baseline and follow-up (mean serum 
phosphorus = 5.81mg/dL at baseline and 4.91 mg/dL at 
SO follow-up, p  < 0.0001), and 27 patients had an in-
crease in prescribed number of days of PD treatment (5.6 
PD treatment days/week at baseline and 6.8 PD treat-
ment days/week at SO follow-up) and serum phosphorus 
decrease of 0.7 mg/dL (5.69 mg/dL at baseline to 4.98 
mg/dL at SO follow-up, p = 0.008). A subset of the pa-
tients (n = 63) who achieved in-range serum phosphorus 
during SO follow-up had serum phosphorus levels >5.5 
mg/dL during baseline (Table 3). Comparing baseline 
and SO follow-up, a notable improvement in serum 
phosphorus (6.54 to 5.10 mg/dL, p  < 0.0001) was ob-
served along with a 53% reduction in PB pill burden (9.9 
to 4.7 pills/day, p < 0.0001). There were nonsignificant 
changes in intact PTH (430 to 391 pg/mL, p = 0.09), cor-
rected calcium (9.31 to 9.36 mg/dL, p = 0.3), and total 
Kt/V (2.0 to 2.2, p = 0.3). Although a slight decrease in 
serum albumin (3.71 to 3.63 g/dL, p  = 0.001) was ob-
served, phosphorus-attuned albumin (0.59 × 103 to 
0.75 × 103, p < 0.0001) and phosphorus-attuned nPCR 
(0.17 × 103 to 0.21 × 103 dL/kg/day, p < 0.0001) increased.
Assessing the Impact of Residual Renal Function on 
PB Pill Burden and Serum Phosphorus Levels
In Table 4, patients are stratified by their baseline Kru. 
The Kru >3 group had more patients with baseline and SO 
follow-up serum phosphorus levels ≤5.5 mg/dL (40.2 and 
52.8%, respectively) when compared to patients for whom 
Kru was not measured (15.6 and 31.3%) and patients with 
Kru ≤ 3 (14.8 and 25.4%). Patients with Kru >3 also had 
lower baseline and SO follow-up PB pills/day (6.7 and 3.7 
pills, respectively) when compared to patients for whom 
Kru was not measured (10.7 and 4.4 pills) and patients 
with Kru ≤3 (10.6 and 4.4 pills). 
Discussion
The current retrospective analysis included patients 
treated under routine care and the analysis had no impact 
on the prescription or treatment of the patients. The pa-
tients did not go through a wash-out period and the current 
analysis relied on physician judgment and preference in PB 
choice. Compared to a representative national sample of 
dialysis patients, with 34% of patients with serum phospho-
rus >5.5 mg/dL [22], the patients in our analysis could be 
considered difficult to treat, as 74% had serum phosphorus 
>5.5 mg/dL. However, a 72% increase of patients in-range 
for serum phosphorus (≤5.5 mg/dL) was achieved with SO, 
with an absolute level of 44.4% of patients in-range at 
6 months and a 57% reduction in PB pills/day. 
Nonadherence to prescribed PB regimen has been re-
ported in 62% of dialysis patients [18]. PB pill burden is a 
cited determinant of PB adherence [6]. Thus, the ob-
served average pill burden decreased from 10 to 5 pills/
day is favorable. The increase in adherence to PB therapy 
may be a factor in the improvements in serum phospho-
rus control in patients prescribed SO. 
Floege et al. [20], as a sub-analysis of a phase III study, 
focused on PD patients over 1 year of follow-up and 
found SO effective for the lowering of serum phosphorus 
levels. Although patients in the SO arm had higher base-
line serum phosphorus levels when compared to the 
sevelamer arm (7.5 mg/dL compared to 6.7 mg/dL), there 
were similar proportion of patients who achieved within-
range serum phosphorus at 24 and 52 weeks in the SO 
(57.1 and 62.5%) and sevelamer (60.7 and 64.3%) arms. 
This was accomplished with 58% lower pill burden when 
using SO compared to sevelamer, which is comparable to 
the findings of our analysis.
In this analysis, we also used 2 novel metrics to ac-
count for the role of nutritional status in the manage-
PB pills/day
Baseline































Fig. 2. Percent of patients with monthly serum phosphorus ≤ 5.5 
mg/dL at baseline and SO follow-up. PB pills/day for patients with 
in-range serum phosphorus decreased from (9.7, 8.8, and 9.0) at 
baseline to (3.9, 4.4, 4.2, 4.4, 4.5, and 4.8) at SO follow-up. SO, su-
croferric oxyhydroxide; PB, phosphate binder.
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Table 3. Comparison of clinical parameters for patients with in-range phosphorus during SO follow-up
Parameter Baseline SO follow-up p value
Patients with serum phosphorus ≤5.5 mg/dL for ≥3 months of SO follow-up (n = 110)
PB pills/day* 9.3 (0.2) 4.4 (0.2) <0.0001
Serum phosphorus, mg/dL 5.81 (0.08) 4.97 (0.07) <0.0001
Albumin-corrected calcium, mg/dL 9.43 (0.06) 9.36 (0.06) 0.08
Intact PTH, pg/mL 406 (33) 425 (32) 0.4
Weight, kg 88.1 (2.3) 87.5 (2.3) 0.3
Serum albumin, g/dL 3.70 (0.03) 3.64 (0.03) <0.001
Phosphorus-attuned albumin, ×103 0.68 (0.01) 0.77 (0.01) <0.0001
Phosphorus-attuned nPCR, ×103 dL/kg/day 0.18 (0.01) 0.21 (0.01) <0.001
Serum creatinine, mg/dL 10.3 (0.4) 10.2 (0.4) 0.12
Kru, mL/min/1.73 m2 3.58 (0.38) 3.25 (0.34) 0.3
PD Kt/V 1.57 (0.12) 1.73 (0.09) 0.3
Total Kt/V 2.2 (0.1) 2.3 (0.1) 0.3
Subset of patients with serum phosphorus >5.5 mg/dL at baseline (n = 63)
PB pills/day** 9.9 (0.3) 4.7 (0.3) <0.0001
Serum phosphorus, mg/dL 6.54 (0.10) 5.10 (0.08) <0.0001
Albumin-corrected calcium, mg/dL 9.31 (0.09) 9.36 (0.08) 0.3
Intact PTH, pg/mL 430 (32) 391 (30) 0.087
Weight, kg 85.9 (2.7) 87.1 (2.7) 0.007
Serum albumin, g/dL 3.71 (0.04) 3.63 (0.04) 0.001
Phosphorus-attuned albumin, ×103 0.59 (0.01) 0.75 (0.01) <0.0001
Phosphorus-attuned nPCR, ×103 dL/kg/day 0.17 (0.01) 0.21 (0.01) <0.0001
Serum creatinine, mg/dL 11.7 (0.5) 11.3 (0.5) 0.002
Kru, mL/min/1.73 m2 2.71 (0.44) 2.40 (0.37) 0.5
PD Kt/V 1.59 (0.17) 1.80 (0.13) 0.3
Total Kt/V 2.0 (0.2) 2.2 (0.1) 0.3
Values are expressed as least-squared means (SE), p values compare least-squared means between treatment periods.
* Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 68). Follow-up 
PB pill burden for patients with no baseline binder available through FreseniusRx (n = 42) was found to be 4.1 SO pills/day.
** Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 29). Follow-up 
PB pill burden for patients with no baseline binder available through FreseniusRx (n = 34) was found to be 4.4 SO pills/day.
Kru, residual urea clearance; nPCR, normalized protein catabolic rate; PD, peritoneal dialysis; PTH, parathyroid hormone; SO, su-
croferric oxyhydroxide; PB, phosphate binder.
Table 4. Comparison of pill burden and serum phosphorus by Kru at baseline
Parameter No Kru recorded (n = 64) Kru ≤3 mL/min/1.73 m2 (n = 122) Kru >3 mL/min/1.73 m2 (n = 72) 
BL SO p value BL SO p value BL SO p value
PB pills/day* 10.7 (0.3) 4.4 (0.3) <0.0001 10.6 (0.3) 4.4 (0.3) <0.0001 6.7 (0.3) 3.7 (0.3) <0.0001
Serum phosphorus, mg/dL 6.57 (0.16) 6.21 (0.15) 0.001 6.96 (0.14) 6.52 (0.13) <0.0001 5.97 (0.16) 5.85 (0.15) 0.22
Patients with serum 
phosphorus ≤5.5 mg/dL
10/64 (15.6) 20/64 (31.3) 0.008 18/122 (14.8) 31/122 (25.4) 0.012 29/72 (40.2) 38/72 (52.8) 0.049
Values are expressed as least-squared means (SE) for continuous variables, and n/n (%) for categorical variables.
p values compare summary estimates between treatment periods.
* PB pill burden was calculated only for patients who received PB prescriptions through FreseniusRx.
BL, baseline; SO, sucroferric oxyhydroxide follow-up; Kru, residual urea clearance; PB, phosphate binder.
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ment of phosphorus, that is, phosphorus-attuned albu-
min and nPCR, in that serum albumin and nPCR were 
each divided by serum phosphorus respectively. These 
2 metrics are meant to address the concern that lower-
ing serum phosphorus by restricting dietary protein 
intake (represented by nPCR) may cause more harm 
[23, 24], and that lower protein intake is associated 
with lower serum albumin in dialysis patients [25]. In-
deed, both low nPCR and low serum albumin levels are 
associated with worse outcomes including higher mor-
tality in dialysis patients. Hence, controlling serum 
phosphorus without restricting dietary protein intake 
or without lowering serum albumin is the preferred 
goal.
Patients with serum phosphorus ≤5.5 mg/dL during 
SO follow-up had a mean reduction in serum phosphorus 
from 5.81 to 4.97 mg/dL (p < 0.0001) and a 54% reduction 
in PB pills/day. Significant improvements in phosphorus-
attuned albumin (0.68 × 103 to 0.77 × 103, p < 0.0001) and 
phosphorus-attuned nPCR (0.18 × 103 to 0.21 × 103 dL/
kg/day, p < 0.001) were also observed. In patients who 
achieved in-range serum phosphorus during SO follow-
up but had serum phosphorus levels >5.5 mg/dL during 
baseline, a notable improvement in serum phosphorus 
(6.54 to 5.1 mg/dL, p < 0.0001) and iPTH (430 to 391 pg/
mL, p = 0.09) were observed, along with a 53% reduction 
in PB pills/day (9.7 to 4.6, p < 0.0001) Treatment with cal-
cimimetics and active vitamin D for all patients and pa-
tients with in-range serum phosphorus is shown in online 
supplementary Tables S3, S4. Phosphorus-attuned albu-
min (0.59 × 103 to 0.75  103, p < 0.0001) and phosphorus-
attuned nPCR (0.17 × 103 to 0.21 × 103 dL/kg/day, p < 
0.0001) also increased from baseline. These changes may 
show the benefits of achieving in-range serum phospho-
rus levels. 
Residual renal function is a contributor to phosphate 
clearance in PD patients [26]; thus, we stratified patients 
based on Kru at baseline. Patients with Kru >3 had a higher 
percentage with in-range serum phosphorus levels at 
baseline and SO follow-up when compared to patients 
without baseline Kru measured or Kru ≤3. There was also 
a lower number of PB pills/day in the patients with Kru >3 
at both baseline (6.7) and SO follow-up (3.7) compared to 
baseline (10.7 and 10.6) and SO follow-up (4.4 and 4.4) for 
patients without recorded Kru and Kru ≤3, respectively. 
SO is an iron-based PB thus anemia and iron indices 
were analyzed. The changes in ferritin and TSAT levels 
were consistent with those mentioned in prior reports of 
minimal iron absorption in phase III clinical trial results 
[20, 27]. Patients not treated with IV iron during the 
phase III clinical trial showed small mean increase in se-
rum ferritin (+71.9) and TSAT (+3.9%) between weeks 24 
and 52 [27]. 
Limitations of our study include utilization of exist-
ing clinical records. Although the results may be more 
generalizable, possible errors or missing data from the 
clinical database are possible. Our analysis relies on 
pharmacy fills, which allows for good accuracy for tim-
ing and pills/day. However, follow-up ends when pa-
tient switches their pharmacy, even if medication is not 
discontinued. Reasons for patient being switched from 
their baseline PB to SO or discontinuing SO during fol-
low-up are not available but may include non-adher-
ence to filling prescriptions, adverse events, switch to 
another pharmacy, insurance coverage, and out of 
pocket costs. Although dietitians provide nutritional 
education to patients using approved educational ma-
terials, exact dietetic advice was not sufficiently record-
ed in the EHR. Reasons for discontinuation of baseline 
or follow-up PBs were not available. Also, there is no 
independent unexposed group available for compari-
son with the SO group, and so the SO group acts as 
their own comparator group during baseline. 
Conclusion
In conclusion, the number of prescribed PB pills/day 
was reduced by half among adult PD patients treated with 
SO, while the proportion of patients who achieved in-
range serum phosphorus (serum phosphorus ≤5.5 mg/
dL) increased.
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